1367454-06-5

Basic information

• Product Name: C₁₆H₂₂N₂O₄S
• Synonyms: C₁₆H₂₂N₂O₄S
• CAS NO: 1367454-06-5
• Molecular Weight: 338.428
• Mol File: 1367454-06-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₁₆H₂₂N₂O₄S(CAS DataBase Reference)
• NIST Chemistry Reference: C₁₆H₂₂N₂O₄S(1367454-06-5)
• EPA Substance Registry System: C₁₆H₂₂N₂O₄S(1367454-06-5)

Safety Data

• Hazardous Substances Data: 1367454-06-5(Hazardous Substances Data)

Upstream product

• 65-82-7 N-acetyl-l-methionine 
• 94-09-7 p-aminoethylbenzoate 

Downstream Products

• 1355150-29-6 (S)-4-(2-acetamido-4-(methylthio)butanamido)benzoic acid 
• 1258550-68-3 (S)-4-(2-acetamido-4-(methylthio)butanamido)-N-(3-nitro-4-(2-(phenylthio)ethylamino)phenylsulfonyl)benzamide 

Relevant articles and documents

Design, synthesis, and activity evaluation of broad-spectrum small-molecule inhibitors of anti-apoptotic Bcl-2 family proteins: Characteristics of broad-spectrum protein binding and its effects on anti-tumor activity

On the basis of the comparison of the structure of the Bim BH3: Bcl-x L complex and that of the ABT-737: Bcl-xL complex, a series of class A compounds were designed. These compounds had the basic skeleton of ABT-737 and the h2 residues of Bim BH3. These residues had shown themselves to be relevant to Bim BH3's broad-spectrum binding properties in saturation mutagenesis assays. Unlike ABT-737, which is a selective inhibitor of anti-apoptotic members of the Bcl-2 protein family, the class A compounds showed broad-spectrum binding activity to target proteins similar to those of Bim BH3 peptide. Then class B compounds were synthesized by modifying the structure of the most effective class A compound, A-4. Most of these class B compounds showed better binding affinity to the target proteins than the class A compounds had. They also showed themselves more effective than ABT-737 at inhibiting growth in multiple tumor cell lines known to express Bcl-x L, Bcl-2, and Mcl-1 proteins at high levels. Compounds B-11 and B-12 had the strongest anti-tumor activity of any compounds we produced. This study suggests that it is feasible to design small-molecule inhibitors based on the structure of Bim BH3, which shows broad-spectrum binding to Bcl-xL, Bcl-2, and Mcl-1 proteins. Our results also suggest that the broad-spectrum properties of small-molecule inhibitors binding to target proteins play a critical role in inhibiting the growth of many tumor cells. Finally, our study provides a series of lead compounds that merit further research into anti-cancer therapeutics.